The Glutamate Receptor Ionotropic NMDA 2 pipeline drugs market research report outlays comprehensive information on the Glutamate Receptor Ionotropic NMDA 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Glutamate Receptor Ionotropic NMDA 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Cardiovascular, Respiratory, and Dermatology which include the indications Major Depressive Disorder, Schizophrenia, Cardiac Arrest, Orthostatic Hypotension, Idiopathic Pulmonary Fibrosis, Chronic Cough, and Burns. It also reviews key players involved in Glutamate Receptor Ionotropic NMDA 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Glutamate Receptor Ionotropic NMDA 2 pipeline targets constitutes close to 19 molecules. Out of which, approximately 17 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 6, 2, 7, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Glutamate Receptor Ionotropic NMDA 2 overview
Glutamate receptor ionotropic NMDA 2 (GRIN2) receptor is a receptor of glutamate, the primary excitatory neurotransmitter in the human brain. It plays an integral role in synaptic plasticity, which is a neuronal mechanism believed to be the basis of memory formation. NMDA receptors also appear to have involvement in a process called excitotoxicity. Excitotoxicity may play a role in the pathophysiology of a variety of diseases such as epilepsy and Alzheimer’s disease.
For a complete picture of Glutamate Receptor Ionotropic NMDA 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
